Fair Value Disclosures (Tables)

9 Months Ended

Aug. 31, 2022

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis

The following is a summary of our financial assets and liabilities that are accounted for at fair value on a recurring basis, excluding Investments at fair value based on net asset value (“NAV”) of $1.30 billion and $1.01 billion at August 31, 2022 and November 30, 2021, respectively, by level within the fair value hierarchy (in thousands):

	August 31, 2022
	Level 1		Level 2		Level 3		Counterparty and Cash Collateral Netting (1)		Total
Assets:
Financial instruments owned:
Corporate equity securities	$	3,270,145	$	92,502	$	195,766	$	—	$	3,558,413
Corporate debt securities	—		3,264,406		18,212		—		3,282,618
Collateralized debt obligations and collateralized loan obligations	—		440,441		49,928		—		490,369
U.S. government and federal agency securities	4,303,598		55,547		—		—		4,359,145
Municipal securities	—		206,214		—		—		206,214
Sovereign obligations	643,476		774,861		—		—		1,418,337
Residential mortgage-backed securities	—		1,564,010		25,743		—		1,589,753
Commercial mortgage-backed securities	—		301,004		31,610		—		332,614
Other asset-backed securities	—		226,140		91,493		—		317,633
Loans and other receivables	—		2,511,984		117,594		—		2,629,578
Derivatives	1,067		3,081,967		15,934		(2,725,042)		373,926
Investments at fair value	—		3,705		139,220		—		142,925
Total financial instruments owned, excluding Investments at fair value based on NAV	$	8,218,286	$	12,522,781	$	685,500	$	(2,725,042)	$	18,701,525
Securities received as collateral	$	149,586	$	—	$	—	$	—	$	149,586
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities	$	1,793,307	$	37,798	$	2,570	$	—	$	1,833,675
Corporate debt securities	—		1,940,464		427		—		1,940,891
Collateralized debt obligations and collateralized loan obligations	—		328		354		—		682
U.S. government and federal agency securities	2,601,469		—		—		—		2,601,469
Sovereign obligations	697,326		783,199		—		—		1,480,525
Commercial mortgage-backed securities	—		3,800		455		—		4,255
Loans	—		2,209,866		12,694		—		2,222,560
Derivatives	81		3,916,772		88,432		(2,556,284)		1,449,001
Total financial instruments sold, not yet purchased	$	5,092,183	$	8,892,227	$	104,932	$	(2,556,284)	$	11,533,058
Other secured financings	$	—	$	—	$	2,362	$	—	$	2,362
Obligation to return securities received as collateral	$	149,586	$	—	$	—	$	—	$	149,586
Long-term debt	$	—	$	796,295	$	721,115	$	—	$	1,517,410

(1)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.

	November 30, 2021
	Level 1		Level 2		Level 3		Counterparty and Cash Collateral Netting (1)		Total
Assets:
Financial instruments owned:
Corporate equity securities	$	2,567,690	$	199,244	$	76,082	$	—	$	2,843,016
Corporate debt securities	—		3,836,303		11,803		—		3,848,106
Collateralized debt obligations and collateralized loan obligations	—		579,518		31,944		—		611,462
U.S. government and federal agency securities	3,045,295		68,784		—		—		3,114,079
Municipal securities	—		509,559		—		—		509,559
Sovereign obligations	899,086		654,199		—		—		1,553,285
Residential mortgage-backed securities	—		1,168,246		1,477		—		1,169,723
Commercial mortgage-backed securities	—		196,419		2,333		—		198,752
Other asset-backed securities	—		337,022		93,524		—		430,546
Loans and other receivables	—		3,363,050		74,585		—		3,437,635
Derivatives	4,429		3,858,848		10,248		(3,304,566)		568,959
Investments at fair value	—		4,236		34,557		—		38,793
Total financial instruments owned, excluding Investments at fair value based on NAV	$	6,516,500	$	14,775,428	$	336,553	$	(3,304,566)	$	18,323,915
Securities received as collateral	$	7,289	$	—	$	—	$	—	$	7,289
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities	$	1,671,696	$	19,654	$	4,635	$	—	$	1,695,985
Corporate debt securities	—		2,111,777		482		—		2,112,259
U.S. government and federal agency securities	2,457,420		—		—		—		2,457,420
Sovereign obligations	935,801		593,040		—		—		1,528,841
Residential mortgage-backed securities	—		719		—		—		719
Commercial mortgage-backed securities	—		—		210		—		210
Loans	—		2,476,087		15,770		—		2,491,857
Derivatives	1,815		5,024,682		78,017		(3,701,010)		1,403,504
Total financial instruments sold, not yet purchased	$	5,066,732	$	10,225,959	$	99,114	$	(3,701,010)	$	11,690,795
Other secured financings	$	—	$	76,883	$	25,905	$	—	$	102,788
Obligation to return securities received as collateral	$	7,289	$	—	$	—	$	—	$	7,289
Long-term debt	$	—	$	961,866	$	881,732	$	—	$	1,843,598

(1)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.

Investments Measured at Fair Value Based on Net Asset Value Per Share

The following tables present information about our investments in entities that have the characteristics of an investment company (in thousands):

	August 31, 2022
	Fair Value (1)		Unfunded Commitments
Equity Long/Short Hedge Funds (2)	$	452,867	$	—
Equity Funds (3)	61,825		37,307
Commodity Funds (4)	25,671		—
Multi-asset Funds (5)	406,183		—
Other Funds (6)	352,977		65,916
Total	$	1,299,523	$	103,223

	November 30, 2021
	Fair Value (1)		Unfunded Commitments
Equity Long/Short Hedge Funds (2)	$	466,231	$	—
Equity Funds (3)	32,412		10,593
Commodity Funds (4)	24,401		—
Multi-asset Funds (5)	390,224		—
Other Funds (6)	99,054		36,090
Total	$	1,012,322	$	46,683

(1)Where fair value is calculated based on NAV, fair value has been derived from each of the funds’ capital statements.

(2)This category includes investments in hedge funds that invest, long and short, primarily in both public and private equity securities in domestic and international markets. At August 31, 2022 and November 30, 2021, approximately 57% and 74%, respectively, became redeemable quarterly with 90 days prior written notice on December 31, 2021. At August 31, 2022 and November 30, 2021, approximately 37% and 21%, respectively, of the fair value of investments in this category cannot be redeemed because these investments include restrictions that do not allow for redemption before November 30, 2023. The remaining investments are redeemable quarterly with 60 days prior written notice.

(3)The investments in this category include investments in equity funds that invest in the equity of various U.S. and foreign private companies in a broad range of industries. These investments cannot be redeemed; instead, distributions are received through the liquidation of the underlying assets of the funds which are primarily expected to be liquidated in approximately one to thirteen years.

(4)This category includes investments in a hedge fund that invests, long and short, primarily in commodities. These investments are redeemable quarterly with 60 days prior written notice.

(5)This category includes investments in hedge funds that invest, long and short, primarily in multi-asset securities in domestic and international markets in both the public and private sectors. At August 31, 2022 and November 30, 2021, investments representing approximately 76% and 78%, respectively, of the fair value of investments are redeemable monthly with 60 days prior written notice. At August 31, 2022 and November 30, 2021, approximately 17% and 22%, respectively, of the fair value of investments are redeemable quarterly with 90 days prior written notice. At August 31, 2022, the remaining investments cannot be redeemed because these investments include restrictions that do not allow for redemption before April 1, 2024.

(6)This category primarily includes investments in a fund that invests in short-term trade receivables and payables that are expected to generally be outstanding between 90 to 120 days and short-term credit instruments, as well as investments in a fund that invests in distressed and special situations long and short credit strategies across sectors and asset types. Investments in this category are primarily redeemable quarterly with 90 days prior written notice.

Summary of Changes in Fair Value of Financial Assets and Liabilities Classified as Level 3

The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended August 31, 2022 (in thousands):

	Three Months Ended August 31, 2022
	Balance at May 31, 2022		Total gains/losses (realized and unrealized) (1)		Purchases		Sales		Settlements		Issuances		Net transfers into/ (out of) Level 3		Balance at August 31, 2022		For instruments still held at  August 31, 2022, changes in unrealized gains/(losses) included in:
																	Earnings (1)		Other comprehensive income (1)
Assets:
Financial instruments owned:
Corporate equity securities	$	199,468	$	(2,161)	$	92	$	(189)	$	—	$	—	$	(1,444)	$	195,766	$	(2,254)	$	—
Corporate debt securities	20,813		(605)		759		(1,183)		—		—		(1,572)		18,212		699		—
CDOs and CLOs	49,858		685		13,133		(4,553)		(3,604)		—		(5,591)		49,928		(9,369)		—
RMBS	1,059		(3,596)		94		—		(32)		—		28,218		25,743		(2,158)		—
CMBS	1,870		(2,663)		—		—		—		—		32,403		31,610		(621)		—
Other ABS	84,778		(1,800)		17,487		—		(13,217)		—		4,245		91,493		(7,432)		—
Loans and other receivables	137,752		1,616		7,065		(21,492)		(325)		—		(7,022)		117,594		1,536		—
Investments at fair value	118,319		19,405		2,184		(48)		(640)		—		—		139,220		19,381		—
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities	$	3,749	$	(278)	$	(940)	$	39	$	—	$	—	$	—	$	2,570	$	(268)	$	—
Corporate debt securities	401		26		—		—		—		—		—		427		(28)		—
CDOs and CLOs	—		(29)		—		383		—		—		—		354		29		—
CMBS	385		—		—		70		—		—		—		455		—		—
Loans	18,283		157		(16,983)		1,937		—		—		9,300		12,694		(1,428)		—
Net derivatives (2)	74,997		(23,380)		(1,929)		—		(20,954)		—		43,764		72,498		19,719		—
Other secured financings	2,362		—		—		—		—		—		—		2,362		—		—
Long-term debt	739,353		(59,521)		—		—		—		—		41,283		721,115		75,930		(16,409)

(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes within Long-term debt are included in our Consolidated Statement of Comprehensive Income, net of tax.

(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.

The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the nine months ended August 31, 2022 (in thousands):

	Nine Months Ended August 31, 2022
	Balance at November 30, 2021		Total gains/losses (realized and unrealized) (1)		Purchases		Sales		Settlements		Issuances		Net transfers into/ (out of) Level 3		Balance at August 31, 2022		For instruments still held at  August 31, 2022, changes in unrealized gains/(losses) included in:
																	Earnings (1)		Other comprehensive income (1)
Assets:
Financial instruments owned:
Corporate equity securities	$	76,082	$	46,147	$	79,729	$	(2,941)	$	(298)	$	—	$	(2,953)	$	195,766	$	45,408	$	—
Corporate debt securities	11,803		3,596		12,689		(16,513)		(9)		—		6,646		18,212		1,537		—
CDOs and CLOs	31,944		2,573		34,756		(18,933)		(8,178)		—		7,766		49,928		(10,371)		—
RMBS	1,477		(6,099)		28,067		(187)		(152)		—		2,637		25,743		(2,894)		—
CMBS	2,333		(18,549)		—		—		—		—		47,826		31,610		(2,420)		—
Other ABS	93,524		(1,446)		51,966		(18,489)		(36,349)		—		2,287		91,493		(17,168)		—
Loans and other receivables	74,585		(6,635)		107,225		(63,530)		(1,256)		—		7,205		117,594		(6,955)		—
Investments at fair value	34,557		46,109		74,499		(48)		(15,897)		—		—		139,220		45,512		—
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities	$	4,635	$	(3,708)	$	(3,255)	$	4,898	$	—	$	—	$	—	$	2,570	$	2,781	$	—
Corporate debt securities	482		15		(70)		—		—		—		—		427		(23)		—
CDOs and CLOs	—		(29)		—		383		—		—		—		354		29		—
CMBS	210		—		—		245		—		—		—		455		—		—
Loans	15,770		94		(22,566)		5,417		—		—		13,979		12,694		(1,478)		—
Net derivatives (2)	67,769		(152,927)		(1,559)		1,285		—		21,024		136,906		72,498		150,713		—
Other secured financings	25,905		—		—		—		(23,543)		—		—		2,362		—		—
Long-term debt	881,732		(316,778)		—		—		—		89,263		66,898		721,115		265,288		51,490

(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes within Long-term debt are included in our Consolidated Statement of Comprehensive Income, net of tax.

(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.

The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended August 31, 2021 (in thousands):

	Three Months Ended August 31, 2021
	Balance at May 31, 2021		Total gains/losses (realized and unrealized) (1)		Purchases		Sales		Settlements		Issuances		Net transfers into/ (out of) Level 3		Balance at August 31, 2021		For instruments still held at August 31, 2021, changes in unrealized gains/(losses) included in:
																	Earnings (1)		Other comprehensive income (1)
Assets:
Financial instruments owned:
Corporate equity securities	$	71,724	$	14,302	$	208	$	(1,488)	$	(16)	$	—	$	338	$	85,068	$	15,390	$	—
Corporate debt securities	7,985		405		14,898		(17,317)		(20)		—		2,205		8,156		192		—
CDOs and CLOs	26,466		2,539		50,199		(33,234)		(1,518)		—		8,014		52,466		(730)		—
RMBS	6,033		(42)		—		(417)		(61)		—		(4,077)		1,436		(14)		—
CMBS	1,176		(103)		1,607		—		—		—		—		2,680		1,530		—
Other ABS	70,555		30		18,611		(274)		(14,426)		—		2,937		77,433		(3,145)		—
Loans and other receivables	119,550		(463)		14,796		(29,557)		(5,873)		—		(8,118)		90,335		817		—
Investments at fair value	40,385		151		16		—		(371)		—		—		40,181		151		—
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities	$	4,462	$	(75)	$	—	$	—	$	—	$	—	$	—	$	4,387	$	75	$	—
Corporate debt securities	927		(7)		—		—		—		—		(392)		528		7		—
CMBS	35		—		—		105		—		—		—		140		—		—
Loans	20,389		(8)		(3,118)		1,710		—		—		6,239		25,212		6		—
Net derivatives (2)	227,058		20,869		(1,868)		—		665		—		(79,662)		167,062		(22,433)		—
Other secured financings	2,493		—		—		—		—		—		—		2,493		—		—
Long-term debt	795,098		(17,106)		—		—		—		22,330		(14,710)		785,612		13,204		3,902

(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes within Long-term debt are included in our Consolidated Statement of Comprehensive Income, net of tax.

(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.

The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the nine months ended August 31, 2021 (in thousands):

	Nine Months Ended August 31, 2021
	Balance at November 30, 2020		Total gains/losses (realized and unrealized) (1)		Purchases		Sales		Settlements		Issuances		Net transfers into/ (out of) Level 3		Balance at August 31, 2021		For instruments still held at August 31, 2021, changes in unrealized gains/(losses) included in:
																	Earnings (1)		Other comprehensive income (1)
Assets:
Financial instruments owned:
Corporate equity securities	$	75,797	$	29,430	$	7,900	$	(37,794)	$	(16)	$	—	$	9,751	$	85,068	$	14,231	$	—
Corporate debt securities	23,146		1,600		1,513		(3,721)		(128)		—		(14,254)		8,156		331		—
CDOs and CLOs	10,513		6,745		58,868		(29,277)		(1,916)		—		7,533		52,466		(4,716)		—
RMBS	21,826		(195)		157		(784)		(291)		—		(19,277)		1,436		(123)		—
CMBS	2,003		134		2,590		(393)		(1,639)		—		(15)		2,680		741		—
Other ABS	79,995		4,770		38,785		(26,642)		(25,966)		—		6,491		77,433		(6,955)		—
Loans and other receivables	77,042		10,062		51,933		(55,693)		(5,509)		—		12,500		90,335		1,714		—
Investments at fair value	67,108		(1,942)		144		(23,575)		(1,554)		—		—		40,181		(3,832)		—
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities	$	4,434	$	(12)	$	(22)	$	—	$	—	$	—	$	(13)	$	4,387	$	13	$	—
Corporate debt securities	141		375		—		12		—		—		—		528		(375)		—
CMBS	35		—		(35)		140		—		—		—		140		—		—
Loans	16,635		1,308		(7,182)		14,083		—		—		368		25,212		(4,094)		—
Net derivatives (2)	26,017		33,173		(1,548)		49,871		768		—		58,781		167,062		(33,007)		—
Other secured financings	1,543		—		—		—		—		950		—		2,493		—		—
Long-term debt	676,028		25,323		—		—		—		58,000		26,261		785,612		31,992		(57,315)

(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes within Long-term debt are included in our Consolidated Statement of Comprehensive Income, net of tax.

(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.

Quantitative Information about Significant Unobservable Inputs Used in Level 3 Fair Value Measurements

The tables below present information on the valuation techniques, significant unobservable inputs and their ranges for our financial assets and liabilities, subject to threshold levels related to the market value of the positions held, measured at fair value on a recurring basis with a significant Level 3 balance. The range of unobservable inputs could differ significantly across different firms given the range of products across different firms in the financial services sector. The inputs are not representative of the inputs that could have been used in the valuation of any one financial instrument (i.e., the input used for valuing one financial instrument within a particular class of financial instruments may not be appropriate for valuing other financial instruments within that given class). Additionally, the ranges of inputs presented below should not be construed to represent uncertainty regarding the fair values of our financial instruments; rather, the range of inputs is reflective of the differences in the underlying characteristics of the financial instruments in each category.

For certain categories, we have provided a weighted average of the inputs allocated based on the fair values of the financial instruments comprising the category. We do not believe that the range or weighted average of the inputs is indicative of the reasonableness of uncertainty of our Level 3 fair values. The range and weighted average are driven by the individual financial instruments within each category and their relative distribution in the population. The disclosed inputs when compared with the inputs as disclosed in other periods should not be expected to necessarily be indicative of changes in our estimates of unobservable inputs for a particular financial instrument as the population of financial instruments comprising the category will vary from period to period based on purchases and sales of financial instruments during the period as well as transfers into and out of Level 3 each period.

August 31, 2022
Financial Instruments Owned:	Fair Value (in thousands)		Valuation Technique	Significant Unobservable Input(s)	Input / Range				Weighted Average
Corporate equity securities	$	195,766
Non-exchange-traded securities			Market approach	Price	$1		-	$366	$81
Corporate debt securities	$	18,212	Market approach	EBITDA multiple	3.8				—
			Scenario analysis	Estimated recovery percentage	6%				—
CDOs and CLOs	$	49,928	Discounted cash flows	Constant prepayment rate	20%				—
				Constant default rate	2%				—
				Loss severity	70%				—
				Discount rate/yield	20	%	-	22%	20%
			Market approach	Price	$69		-	$102	$87
CMBS	$	31,610	Market approach	Spreads (basis points (“bps”))	322 bps		-	334 bps	326 bps
Other ABS	$	75,439	Discounted cash flows	Constant default rate	2%				—
				Loss severity	85%				—
				Discount rate/yield	7	%	-	21%	15%
				Cumulative loss rate	7	%	-	24%	19%
				Duration (years)	0.9		-	1.6	1.2
			Market approach	Price	$32		-	$100	$97
Loans and other receivables	$	117,594	Market approach	Price	$45		-	$154	$118
			Scenario analysis	Estimated recovery percentage	32	%	-	100%	97%
Derivatives	$	8,440
Equity options			Volatility benchmarking	Volatility	23	%	-	52%	41%
Investments at fair value	$	139,220
Private equity securities			Market approach	Price	$0		-	$14,919	$487
Financial Instruments Sold, Not Yet Purchased:
Corporate equity securities	$	2,570
Non-exchange-traded securities			Market approach	Price	$1				—
Corporate debt securities	$	427	Scenario analysis	Estimated recovery percentage	6%				—
Loans	$	12,694	Market approach	Price	$90		-	$96	$92
			Scenario analysis	Estimated recovery percentage	5%				—
Derivatives	$	82,721
Equity options			Volatility benchmarking	Volatility	29	%	-	68%	50%
Other secured financings	$	2,362	Scenario analysis	Estimated recovery percentage	13	%	-	39%	30%
Long-term debt
Structured notes	$	721,115	Market approach	Price	$51		-	$104	$72
				Price	€60		-	€102	€78

November 30, 2021
Financial Instruments Owned	Fair Value (in thousands)		Valuation Technique	Significant Unobservable Input(s)	Input / Range				Weighted Average
Corporate equity securities	$	75,694
Non-exchange-traded securities			Market approach	Price	$1		-	$366	$208
Corporate debt securities	$	11,803	Market approach	Price	$13		-	$100	$86
CDOs and CLOs	$	31,944	Discounted cash flows	Constant prepayment rate	20%				—
				Constant default rate	2%				—
				Loss severity	25	%	-	30%	26%
				Discount rate/yield	8	%	-	19%	16%
			Market approach	Price	$86		-	$103	$93
CMBS	$	2,333	Scenario analysis	Estimated recovery percentage	81%				—
Other ABS	$	86,099	Discounted cash flows	Constant prepayment rate	0	%	-	35%	31%
				Constant default rate	2	%	-	4%	4%
				Loss severity	60	%	-	85%	55%
				Discount rate/yield	3	%	-	16%	10%
				Cumulative loss rate	7	%	-	20%	14%
				Duration (years)	0.7		-	1.4	1.1
			Market approach	Price	$37		-	$100	$94
Loans and other receivables	$	73,361	Market approach	Price	$31		-	$101	$54
			Scenario analysis	Estimated recovery percentage	9	%	-	100%	42%
Derivatives	$	6,501
Equity options			Volatility benchmarking	Volatility	46%				—
Interest rate swaps			Market approach	Basis points upfront	0.1		-	8.7	3.3
Total return swaps				Price	$100				—
Investments at fair value	$	34,557
Private equity securities			Market approach	Price	$1		-	$152	$48
			Scenario analysis	Estimated recovery percentage	7%				—
Financial Instruments Sold, Not Yet Purchased:
Corporate equity securities	$	4,635
Non-exchange-traded securities			Market approach	Price	$1				—
Loans	$	15,770	Market approach	Price	$31		-	$100	$43
			Scenario analysis	Estimated recovery percentage	50%				—
Derivatives	$	76,533
Equity options			Volatility benchmarking	Volatility	26	%	-	77%	40%
Interest rate swaps			Market approach	Basis points upfront	0.1		-	8.7	3.1
Total return swaps				Price	$100				—
Other secured financings	$	25,905	Scenario analysis	Estimated recovery percentage	13	%	-	98%	92%
Long-term debt
Structured notes	$	881,732	Market approach	Price	$76		-	$115	$94
				Price	€81		-	€113	€103

Summary of Gains (Losses) Due to Changes in Instrument Specific Credit Risk and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables

The following is a summary of gains (losses) due to changes in instrument-specific credit risk on loans, other receivables and debt instruments and gains (losses) due to other changes in fair value on Long-term debt measured at fair value under the fair value option (in thousands):

	Three Months Ended  August 31,				Nine Months Ended  August 31,
	2022		2021		2022		2021
Financial instruments owned:
Loans and other receivables	$	(9,040)	$	(7,273)	$	4,828	$	17,600
Financial instruments sold, not yet purchased:
Loans	$	(832)	$	(574)	$	(121)	$	945
Long-term debt:
Changes in instrument-specific credit risk (1)	$	(5,824)	$	20,478	$	88,309	$	(103,751)
Other changes in fair value (2)	62,476		(26,093)		318,408		61,695

(1)Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.

(2)Other changes in fair value are included in Principal transactions revenues in our Consolidated Statements of Earnings.

The following is a summary of the amounts by which contractual principal is greater than (less than) fair value for loans and other receivables, Other secured financings and Long-term debt measured at fair value under the fair value option (in thousands):

	August 31, 2022		November 30, 2021
Financial instruments owned:
Loans and other receivables (1)	$	5,741,428	$	5,600,648
Loans and other receivables on nonaccrual status and/or 90 days or greater past due (1) (2)	226,577		64,203
Long-term debt	361,044		(38,391)
Other secured financings	2,913		3,432

(1)Interest income is recognized separately from other changes in fair value and is included in Interest revenues in our Consolidated Statements of Earnings.

(2)Amounts include loans and other receivables 90 days or greater past due by which contractual principal exceeds fair value of $93.1 million and $19.7 million at August 31, 2022 and November 30, 2021, respectively.